Godasal® 100
tablets
![GodasalRR 100](javascript:obrazek_big("http://promedcs.cz//en/../img/baleni/600_Godasal skl._03_10.jpg", "en"); "GodasalRR 100")
- Manufacturer:
- PRO.MED.CS Praha a.s.
- Marketing authorisation holder:
- PRO.MED.CS Praha a.s.
- Composition:
- Acidum acetylsalicylicum 100 mg, glycinum 50 mg in 1 tablet.
- Indication group:
- antithrombotic, antiaggregant agent
The following information is for health professionals only.
READ CAREFULLY THIS NOTICE!
Characteristics:
Acetylsalicylic acid in low doses limits aggregation of blood platelets. The mechanism of effect consists in irreversible acetylation of cyclooxygenase enzyme in blood platelets and thus in the inhibition of thromboxan A2 synthesis. Glycine protects the gastric mucosa and by improving the solubility of acetylsalicylic acid increases its biological availability.
Indications:
Godasal® 100 tbl. is intended for the prevention of thromboembolic events in cardiovascular and neurovascular diseases. On physician’s recommendation, this preparation is administered in all forms of ischemic heart disease, including the condition after acute myocardial infarction, after operations on coronary arteries (aorto-coronary bypass, coronary angioplastic operation - PTCA), after cerebral vascular ischemic event (TIA, minor stroke), in obliterating atherosclerosis of the lower extremities, or in chronic fibrillation of the atria, if anticoagulant treatment is contraindicated in the patient.
Contraindications:
Hypersensitivity to acetylsalicylic acid and other salicylates, hemorhagic diathesis, hypoprothrombinemia and thrombocytopenia, gastric and duodenal ulcers, surgical interventions involving major bleeding. The first and last trimester of gravidity, lactation. Caution is necessary when Godasal® 100 tbl. is administered to patients with bronchial asthma, serious liver diseases, gout, allergic patients, during the second trimester of gravidity. Godasal® 100 tbl. is not intended for children.
Undesirable effects:
On Godasal® 100 tbl. administration, GIT complaints (stomachake, microbleeding), sometimes even nausea, vomiting, and diarrhoea may occur. Rarely there develop major bleeding into the stomach and gastric ulcers, allergic reaction (bronchospasm, skin reactions), and hypochromic anemia. Hepatic and renal disorders, hypoglycemia, thrombocytopenia, agranulocytosis, pancytopenia, aplastic anemia, grave skin reaction (Stevens-Johnson and Lyell syndromes) have been sporadically reported. On long-term administration, increased bleeding, manifested by unusual formation of bruises, nasal and gingival bleeding, may occur. Godasal® 100 tbl. decreases the elimination of uric acid. In sensitive patients, it may even induce a fit of gout. Dizziness and tinnitus may occur as signs of overdose.
Interactions:
Godasal® 100 tbl. increases the effect of anticoagulant agents, both coumarin derivatives and heparin, increases the danger of bleeding from the gastrointestinal tract in glucocorticoid therapy and in concomitant alcohol consumption. Godasal® 100 tbl. increases the efficacy of cardiac glycosides, barbiturates and lithium. It increases both the therapeutic and undesirable effects of nonsteroidal antirheumatic agents and methotrexate. It increases the effect of oral antidiabetics (containing sulfonyl urea), sulfonamides, and triiodothyronine. Godasal® 100 tbl. decreases the effect of some antihypertensive agents, diuretics, and antiuratic agents. Antacids can decrease the effect of Godasal® 100 tbl.
Caution:
In long-term administration of acetylsalicylic acid,it is necessary to examine the blood count and the occurrence of occult bleeding. Prior to surgical intervention, including tooth extraction, it is necessary to consider discontinuation of Godasal® 100 tbl. administration.
Dosage:
If not recommended otherwise, adults usually take 1 tablet of Godasal® 100 daily. It is advisable to allow tablets to disintegrate in a small amount of water and drink it, best after meals.
Package:
20, 50 or 100 tablets.
For greater details about the preparation see the product data summary.
Date of the latest revision of the text: September 30, 2009.
The preparation is available on medical prescription only.